CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
thrombolytic therapy +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000552
NCT00000552Phase 3Completed
CompareCT.gov

Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Carelon Research·interventional·Posted Oct 28, 1999·Updated Mar 4, 2014

In Brief

A Phase 3 clinical trial evaluating angioplasty, transluminal, percutaneous coronary, coronary artery bypass, and 1 other intervention for Cardiovascular Diseases and 5 related conditions. Completed.

Detailed Summary

To test if early revascularization, primarily with angioplasty (PTCA) or bypass surgery (CABG), reduced all-cause in-hospital mortality from cardiogenic shock compared to conventional treatment, including thrombolysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Infarction, Myocardial Ischemia, Shock, Cardiogenic
Countries--
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1994
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 26.7 years ago

Interventions

angioplasty, transluminal, percutaneous coronaryprocedure

coronary artery bypassprocedure

thrombolytic therapydrug